Cohance Lifesciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

India Cements Ltd, Tanla Platforms Ltd, Blue Jet Healthcare Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 27 April 2026.

Cohance Lifesciences Ltd soared 19.99% to Rs 432.7 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 15.19 lakh shares were traded on the counter so far as against the average daily volumes of 4.86 lakh shares in the past one month.

India Cements Ltd surged 12.10% to Rs 457.05. The stock was the second biggest gainer in 'A' group. On the BSE, 6.92 lakh shares were traded on the counter so far as against the average daily volumes of 10613 shares in the past one month.

Tanla Platforms Ltd spiked 11.33% to Rs 541.5. The stock was the third biggest gainer in 'A' group. On the BSE, 4.43 lakh shares were traded on the counter so far as against the average daily volumes of 38325 shares in the past one month.

Blue Jet Healthcare Ltd exploded 9.99% to Rs 443.75. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.05 lakh shares were traded on the counter so far as against the average daily volumes of 27090 shares in the past one month.

Epack Durable Ltd rose 8.63% to Rs 253.1. The stock was the fifth biggest gainer in 'A' group. On the BSE, 52724 shares were traded on the counter so far as against the average daily volumes of 37732 shares in the past one month.

Vohra will succeed Vivek Sharma, who is stepping down as executive chairman for personal reasons. Sharma will continue with Cohance as an advisor for the next nine months to ensure a smooth transition.

Vohra is one of the most accomplished leaders in the pharmaceutical industry. Over a career spanning more than three decades, he has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality and operational excellence. Most recently, as CEO and managing director of Cipla, Vohra led the company?s transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform.

The company said the appointment reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of Cohance?s transformation and its next phase of growth.

Commenting on appointment, Umang Vohra said, ?I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance?s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers.

The company?s consolidated net profit dropped 76% to Rs 36.72 crore on 19.5% decline in revenue from operations to Rs 544.55 crore in Q3 FY26 over Q3 FY25.

The board of Cohance Lifesciences at its meeting held on 27 April 2026 has approved the following:

Noted the resignation of Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company with effect from 30 April 2026.

Approved the appointment of Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer with effect from 01 May 2026 and 20 May 2026 respectively.

Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News